1. Scrip
  2. >>Therapy Areas

EC Approves Extended Invokana Indication On Renal Outcomes In DKD

First SGLT2 Inhibitor In Europe To Gain Extended Indication

 
• By John Davis

Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.    

Back_Pain
• Source: Shutterstock

Janssen Pharmaceutical Cos./Mundipharma International Corp. Ltd.’s SGLT2 inhibitor, Invokana (canagliflozin), has become the first drug in nearly 20 years to have its indications in Europe extended to include renal outcomes data from a Phase III study in patients with diabetic kidney disease (DKD) and type 2 diabetes.

The European Commission’s approval, announced by Mundipharma on 1 July, follows a positive recommendation from the EMA’s CHMP in May...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.